Shots:

• Cheplapharm to pay AstraZeneca a total of $400M non-contingent consideration- present value recognised as other operating income upon completion of the transaction- anticipated during the Q4’2020. $250M (of the $400M consideration) will be payable on completion and the remainder in H1’2021
• AstraZeneca has agreed to sell the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (candesartan cilexetil + hydrochlorothiazide) in around 70 countries globally to Cheplapharm
• Atacand is a selective- AT1 subtype angiotensin II receptor antagonist that is indicated for the management of hypertension in adults and children/adolescents- as well as HF in adults

  Ref: AstraZeneca | Image: Financial Times